Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients

Fanny Lebossé¹,²,³, Aurore Inchauspé⁴, A, Maëlle Locatelli¹,², Clothilde Miaglia¹,²,³, Audrey Diederichs¹,², Judith Fresquet¹,², Fleur Chapus⁵,², Kamal Hamed⁴, Barbara Testoni¹,²,³ & Fabien Zoulim¹,²,³

Hepatitis B virus (HBV) covalently closed circular (cccDNA) is the key genomic form responsible for viral persistence and virological relapse after treatment withdrawal. The assessment of residual intrahepatic cccDNA levels and activity after long-term nucleos(t)ide analogues therapy still represents a technical challenge. Quantitative (q)PCR, rolling circle amplification (RCA) and droplet digital (dd)PCR assays were used to quantify residual intrahepatic cccDNA in liver biopsies from 56 chronically HBV infected patients after 3 to 5 years of telbivudine treatment. Activity of residual cccDNA was evaluated by quantifying 3.5 kB HBV RNA (preC/pgRNA) and by assessing cccDNA-associated histone tails post-transcriptional modifications (PTMs) by micro-chromatin immunoprecipitation. Long-term telbivudine treatment resulted in serum HBV DNA suppression, with most of the patients reaching undetectable levels. Despite 38 out of 56 patients had undetectable cccDNA when assessed by qPCR, RCA and ddPCR assays detected cccDNA in all-but-one negative samples. Low preC/pgRNA level in telbivudine-treated samples was associated with enrichment for cccDNA histone PTMs related to repressed transcription. No difference in cccDNA levels was found according to serum viral markers evolution. This panel of cccDNA evaluation techniques should provide an added value for the new proof-of-concept clinical trials aiming at a functional cure of chronic hepatitis B.

Abbreviations

ALT Alanine aminotransferase
cccDNA Covalently closed circular DNA
CHB Chronic hepatitis B
ChIP Chromatin immunoprecipitation
ddPCR Droplet digital PCR
HBeAg Hepatitis B e Antigen
HBsAg Hepatitis B s Antigen
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HIV Human immunodeficiency virus
NUCs Nucleos(t)ides analogues

¹INSERM U1052-Cancer Research Center of Lyon (CRCL), Lyon, France. ²University of Lyon, UMR_S1052, CRCL, Lyon, France. ³Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France. ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ⁵email: barbara.testoni@inserm.fr; fabien.zoulim@inserm.fr
Almost 257 million people worldwide are chronically infected with hepatitis B virus (HBV) and consequently predisposed to an increased risk of cirrhosis and hepatocellular carcinoma (HCC)\(^1\). The hallmark of HBV infection is the presence of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes\(^2\).

cccDNA is a stable episomal viral “minichromosome” and serves as the template for the transcription of all viral RNAs, amongst which is the pre-genomic (pg)RNA, specifically transcribed from cccDNA and not from integrated viral sequences. pgRNA is retrotranscribed by the viral polymerase into relaxed circular DNA (rcDNA) within the newly formed nucleocapsids in the cytoplasm\(^3\). The intrahepatic cccDNA pool can be maintained by both intracellular recycling of nucleocapsids or by new rounds of infection and accounts for: (i) the chronicity of HBV infection, (ii) viral relapse following treatment withdrawal and (iii) for viral reactivation under immunosuppressive conditions for patients with cured HBV infection\(^5,6\). cccDNA is decorated by nucleosomes to form an organized chromatin structure, a so-called viral “minichromosome”, which is epigenetically regulated by host and viral factors (reviewed in\(^7\)). Acetylation of cccDNA-associated histone tails has been correlated in vivo to patients’ viremia levels and intrahepatic cccDNA transcriptional activity\(^8,9\), while the association of histone H3 trimethylation of lysine 9 and 27 with viral transcription levels in vivo is more controversial\(^10,11\).

Nucleos(t)ides analogues (NUCs), the standard-of-care treatment for chronic hepatitis B (CHB), suppress serum viral DNA, but do not have a direct effect on nuclear cccDNA\(^12\). Even if recent data suggest that NUC therapy is unable to completely block intracellular viral DNA synthesis, which may contribute to the continuous replenishment and, thus, to the inability to clear the cccDNA pool\(^13\), long-term therapies decrease intrahepatic cccDNA levels, challenging the sensitivity of current cccDNA quantification techniques. Indeed, in a recent study, Lai et al. failed to detect any intrahepatic cccDNA for half of the 43 patients analyzed after 10 years of NUC therapy, whereas some of the cccDNA-negative samples were positive for pgRNA and total intrahepatic HBV DNA (tHBV DNA)\(^14\). However, it has to be noted that the tHBV DNA assay used in that study spans the HBV S open reading frame, and thus does not exclude amplification of viral integrated sequences in the host genome.

The research priorities to achieve a cure of chronic hepatitis B were recently summarized by the International Coalition to Eliminate HBV (ICE-HBV) consortium and include a better characterization of correlates of cure to help the evaluation of novel drugs in clinical trials\(^15\). The evaluation of cccDNA is thus paramount but still faces several challenges with the need of: (i) more sensitive techniques for cccDNA quantification to overcome the challenges of small size liver samples obtained from liver biopsies and also of low levels of intrahepatic viral DNA during therapy; (ii) coupling cccDNA quantification and cccDNA transcriptional activity evaluation, the latter being appraised by its epigenetic status and pgRNA levels; (iii) investigating the evolution of the number of infected hepatocytes harboring cccDNA in the liver; (iv) developing in-situ, single-cell, single-molecule assays to visualize cccDNA in infected cells.

Here, we report the use of a panel of investigational molecular biology assays to robustly profile HBV replicative markers, in particular levels of cccDNA and its transcriptional activity, in liver biopsies of long-term NUC treated patients. Extensive evaluation by different techniques, including a highly sensitive droplet digital PCR (ddPCR) method and a liver biopsy—adapted chromatin immunoprecipitation (ChIP)—quantitative PCR technique (micro-ChIP), allowed to reveal the presence of detectable cccDNA in all except one patient out of a cohort of 56 patients treated for 3 to 5 years with the nucleoside analogue telbivudine. Moreover, the residual pool of cccDNA was associated with histone post-transcriptional modifications (PTMs) related to repressed transcription.

Results

Patients’ characteristics. At the time of enrolment in the trial (Supplementary Fig. 1), all 56 patients (37 HBeAg(+) and 19 HBeAg(−)) had alanine aminotransferase (ALT) levels higher than the upper limit of normal (ULN) and were classified as chronic hepatitis B (CHB) according to the 2017 EASL clinical practice guidelines\(^16\). The median age was 29 years old, HBV e antigen-positive (HBeAg(+) ) patients being significantly younger than HBV e antigen-negative (HBeAg(−)) ones. Forty-three patients were infected with HBV genotype C and 13 with genotype B (Table 1). Baseline serum HBV DNA and ALT levels tended to be higher for HBeAg(+) patients and there was no significant difference between the two groups in the duration of telbivudine treatment (Table 1). Before treatment, the majority of the patients exhibited low histological scores of necroinflammatory activity and fibrosis although HBeAg(−) group showed a significantly higher proportion of patients with advanced fibrosis (Supplementary Fig. 2).

At the time of liver biopsy, i.e. one week after entry in the CLDT600ACN04E1 study, corresponding to three to five years of telbivudine therapy (Supplementary Fig. 1 and Methods section), all the patients reached ALT levels under the ULN and only 3/56 patients exhibited a detectable serum HBV DNA (all 3 HBeAg(+) patients).

Quantification of intrahepatic viral markers after telbivudine treatment using a qPCR method. Intrahepatic total HBV DNA (tHBV-DNA), cccDNA and 3.5 kb RNA (preC/pgRNA) were first quantified using a qPCR method already described for intrahepatic HBV markers quantification\(^17\) and results are listed in Table 2. tHBV-DNA levels after telbivudine therapy were less than 1 copy per cell in all patients.
Intrahepatic cccDNA level was under the limit of detection for 39 out of 56 (70%) patients (Fig. 1). Baseline HBeAg(+) patients showed a significantly higher proportion of patients with detectable cccDNA (15 out of 37 HBeAg(+) patients) than HBeAg(−) patients, where only 2 out of 19 patients had detectable cccDNA (Table 2). Similar to tHBV-DNA, intrahepatic low levels of 3.5 kb RNA were detected after telbivudine treatment (median of $1.98 \times 10^{-1}$ copies per cell, $2.08 \times 10^{-1}$ copies per cell and $1.98 \times 10^{-1}$ copies per cell, for the entire cohort, HBeAg(+) and HBeAg(−) patients, respectively (Table 2)).

**Table 1.** Demographical and virological patients’ characteristics at baseline. *Data are expressed as median (1st quartile–3rd quartile) b Mann Whitney U test was used for comparison between HBeAg(+) and (−) groups. χ2 test was performed between HBeAg(+) and (−) groups.

| Serum | Virological outcomes | Total cohort (n=56) | Baseline HBeAg(+) patients (n=37) | Baseline HBeAg(−) patients (n=19) | p value |
|-------|----------------------|---------------------|-----------------------------------|----------------------------------|--------|
|       | HBe Ag loss          | 28                  | 28                                | –                                | ns     |
|       | HBe seroconversion   | 15                  | 15                                | –                                | ns     |
|       | Anti-HBe antibodies  | 30                  | 15                                | 15                                | ns     |
|       | HBs Ag loss          | 2                   | 2                                 | 0                                | ns     |
|       | HBs seroconversion   | 0                   | 0                                 | 0                                | ns     |
|       | Serum HBV DNA\(^{ab}\) (detectable/undetectable/missing value) | 3/50/3 | 3/32/2 | 0/18/1 | ns |
| ALT level\(^{cd}\) (IU/L) | 24 (18–38) | 23 (18–31) | 34 (19–48) | ns |
| Liver | Intrahepatic total HBV DNA\(^{ae}\) (copies/cell) | $1.49 \times 10^{-1}$ (5.23 $\times 10^{-2}$–2.61 $\times 10^{-1}$) | $1.76 \times 10^{-2}$ (8.9 $\times 10^{-3}$–2.76 $\times 10^{-2}$) | 7.7 $\times 10^{-5}$ (4.4 $\times 10^{-5}$–2.43 $\times 10^{-5}$) | ns |
|       | Intrahepatic cccDNA\(^{ae}\) (Detectable/undetectable) | 17/39 | 15/22 | 2/17 | 0.002 |
|       | Intrahepatic 3.5 kb RNA\(^{ada}\) (Relative quantity) | $1.98 \times 10^{-1}$ (6.20 $\times 10^{-2}$–6.03 $\times 10^{-1}$) | $2.08 \times 10^{-1}$ (8.18 $\times 10^{-2}$–6.44 $\times 10^{-1}$) | $1.98 \times 10^{-1}$ (5.10 $\times 10^{-2}$–5.74 $\times 10^{-1}$) | ns |

**Table 2.** Patients’ outcomes at the time of liver biopsy. *Data are available for 53 patients. b χ² test between HBeAg(+) and (−) groups. c Data are expressed as median (1st quartile – 3rd quartile). d Mann Whitney U test was used for comparison between HBeAg(+) and (−) groups. e Data for intrahepatic viral DNA and RNA were obtained using the qPCR quantification method (See Patients and Methods section for details).

Intrahepatic cccDNA level was under the limit of detection for 39 out of 56 (70%) patients (Fig. 1). Baseline HBeAg(+) patients showed a significantly higher proportion of patients with detectable cccDNA (15 out of 37 HBeAg(+) patients) than HBeAg(−) patients, where only 2 out of 19 patients had detectable cccDNA (Table 2). Similar to tHBV-DNA, intrahepatic low levels of 3.5 kb RNA were detected after telbivudine treatment (median of $1.98 \times 10^{-1}$ copies per cell, $2.08 \times 10^{-1}$ copies per cell, and $1.98 \times 10^{-1}$ copies per cell, for the entire cohort, HBeAg(+) and HBeAg(−) patients, respectively (Table 2)).

**Intrahepatic cccDNA detection using rolling circle amplification and droplet digital PCR.** To further investigate the presence of cccDNA in the liver samples with undetectable cccDNA by qPCR, we decided to perform two supplementary approaches: RCA and ddPCR (Fig. 1). Among the 39 samples with undetectable cccDNA by qPCR, 29 showed a positive signal after RCA analysis (Figs. 1 and 2). Since the major limitation of RCA technique is that it is not quantitative, we decided to use ddPCR, which has been recently shown to be more sensitive than qPCR in detecting HBV genome in low-level HBV infected samples18–20. We showed that the ddPCR cccDNA assay specifically amplifies episomal HBV DNA over integrated sequences and preferentially recognizes cccDNA over rcDNA (Methods section and Supplementary Fig. 3). In particular, we could confirm that ddPCR is 2 logs more sensitive than qPCR for the quantification of an HBV plasmid, allowing HBV DNA quantification from samples containing as less as 1 copy/µL of HBV genome (Fig. 3a). We also showed that the circular nature of cccDNA did not affect ddPCR efficiency, since the same quantification results were obtained from a circular and a linearized HBV-plasmid template (Fig. 3b). The analysis of HBV-negative liver biopsy samples confirmed the specificity of the technique and served as reference for the settings of thresholds discriminating positive from negative droplets (Fig. 3c).

ccDNA-positive liver samples with qPCR were confirmed to be positive also by ddPCR. Twenty-seven out of 34 samples with undetectable cccDNA by qPCR had a positive cccDNA signal with both RCA and ddPCR (Fig. 4). ddPCR allowed the detection of cccDNA in 6 more patients than RCA while one sample was positive.
only by RCA analysis (Fig. 4). Altogether, after combining qPCR and ddPCR results, intrahepatic cccDNA was detectable in 50 out of 51 telbivudine-treated patients tested with both techniques (5 liver samples were not assessed by ddPCR due to insufficient residual material) (Figs. 1 and 4).

Overall, absolute amounts of cccDNA quantified by ddPCR were 4.43 × 10⁻³ copies/cell for the entire cohort and 7.27 × 10⁻³ and 3.72 × 10⁻³ copies/cell for baseline HBeAg(+) and HBeAg(−) patients, respectively (Table 3). The cccDNA levels measured by ddPCR were significantly lower in samples with undetectable cccDNA by qPCR (median of 3.2 × 10⁻³ copies/cell vs 1.9 × 10⁻² copies/cell in samples negative and positive for cccDNA with qPCR, respectively) (Table 3).

At the time of liver biopsy, 28/37 (76%) HBeAg(+) patients had lost HBeAg and 15/37 (40%) had experienced HBe seroconversion (Table 2). No differences in baseline age, serum HBV DNA and ALT levels were found between patients who experienced or not HBeAg loss and/or seroconversion (Supplementary Table 1). No differences in intrahepatic tHBV-DNA, cccDNA or 3.5 kb RNA levels after telbivudine therapy were reported according to HBeAg loss and/or seroconversion at the time of liver biopsy (Supplementary Table 1 and 2). Two out of 3 patients with detectable serum HBV DNA at the time of liver biopsy showed positive cccDNA when assessed with qPCR, while all of them were positive when tested by ddPCR. No difference of tHBV-DNA or 3.5 kb RNA

---

**Figure 1.** Workflow of intrahepatic covalently closed circular DNA (cccDNA) assessment. Step 1: Frozen liver biopsy samples were first tested for the presence and the level of intrahepatic cccDNA using quantitative PCR (qPCR) method17; Step 2: Rolling Circle Amplification (RCA)35,36 was performed on the 39 qPCR-negative samples and detected cccDNA in 29 of them; Step 3: digital droplet PCR (ddPCR) was performed on qPCR-negative liver samples with available remaining material (28 out of 29 RCA-positive samples and 6 out of 10 RCA-negative samples). ddPCR detected cccDNA for all-but-one samples tested. Overall, intrahepatic cccDNA was detectable in 50 out 51 patients tested when assessed by qPCR or ddPCR. cccDNA covalently closed circular DNA, RCA rolling circle amplification, ddPCR droplet digital PCR.
was found for these patients compared to those with undetectable serum HBV DNA (data not shown). Only two patients (HBeAg(+) at baseline) lost HBsAg after telbivudine therapy, therefore it was not possible to perform

**Figure 2.** Rolling Circle Amplification (RCA) analysis on patients’ liver biopsies. (a) Workflow of RCA set-up in liver biopsies: DNA extracted from frozen-liver biopsies was first amplified with Phi29 polymerase for 21 h at 30 °C. Amplification products were then either digested with SpeI enzyme and analyzed according to Southern Blot technique using HBV-specific cold probes or assessed following a full-length HBV genomic PCR (P1-P2) followed by gel electrophoresis. (b) Examples of Southern Blot following RCA and SpeI digestion on liver biopsies from patients with different cccDNA concentration measured by qPCR and negative (0; H20) and positive controls (PC; plasmid containing a full-length HBV genome). (c) Examples of gel electrophoresis following full-length HBV genomic PCR (P1-P2) performed on RCA products from patients’ liver biopsies with different cccDNA concentration measured by qPCR and negative (0; H20) and positive control (PC; plasmid containing a full-length HBV genome). **MW** molecular weight; 0: negative control (H20); PC positive control (plasmid containing a full-length HBV genome).
statistical analysis in this group of patients (Table 2). However, both had undetectable cccDNA by qPCR, but scored positive by ddPCR quantification.

**cccDNA epigenetic status on telbivudine treatment.** 3.5 kb RNAs are exclusively transcribed from its cccDNA template. Given the low levels of 3.5 kb RNAs found in telbivudine-treated patients, we wondered if it could be explained not only by a low level of its transcriptional template, i.e. cccDNA, but also by a reduction of its transcriptional activity. To test this hypothesis, we performed ChIP analysis on liver samples derived from 10 telbivudine-treated patients with sufficient liver material (4 HBeAg(+), 6 HBeAg(−)). All the patients had qPCR-detectable cccDNA, but did not differ significantly from the cccDNA-qPCR negative
Telbivudine-treated patients not included in ChIP analysis, except for having higher cccDNA levels (Supplementary Table 3). They were compared to 7 untreated CHB patients with active HBV transcription and replication (5 HBeAg(+), 2 HBeAg(−)) (see Supplementary Table 4 for patients’ characteristics). We assessed the levels of cccDNA-associated histone PTMs associated to either active (H3K27Ac, H3K56Ac) or inactive (H3K9me3, H3K27me3) transcription, using GAPDH promoter amplification as a control for antibody specificity (Supplementary Fig. 4a)21. Untreated CHB patients presented a higher 3.5 Kb RNA/cccDNA ratio (median of 160 vs 6.03 in telbivudine-treated group, p = 0.0001, Supplementary Table 4) associated with a significant enrichment of positive histone PTMs on cccDNA (Fig. 5a), while telbivudine-treated patients showed no significant enrichment with respect to No Antibody control of positive histone PTMs, but a significant increase of histone PTMs associated with repressed transcriptional activity, independently from patients’ HBeAg status (Fig. 5b and Supplementary Fig. 4b-c).

Discussion

In the context of the global HBV cure research programs15, the evaluation of the intrahepatic cccDNA amount and its transcriptional activity will be instrumental for the assessment of the efficacy of the novel antiviral strategies under clinical investigation and for the development of non-invasive biomarkers reflecting the pool of cccDNA15.

Here, we propose the use of a panel of molecular assays to robustly assess both cccDNA amount and transcriptional activity in vivo, in liver samples derived from long-term NUC-treated patients. The implementation of ddPCR, together with the adaptation of classic ChIP to small size liver biopsies represent an advent by providing technical tools to evaluate the residual pool of cccDNA and its epigenetic status in the infected liver.

Similar to the study of Lai et al., we found that the majority of the patients had undetectable levels of intrahepatic cccDNA after long course of NUC treatment, when assessed with qPCR technique14. However, in our study, using a more sensitive ddPCR assay, we could detect and quantify intrahepatic cccDNA in all but one tested liver biopsies of telbivudine-treated patients. Importantly, the assay used in this study for cccDNA quantification specifically recognize episomal cccDNA over HBV integrated sequences (Supplementary Fig. 3). The relevance of ddPCR analysis in CHB has already been reported for the investigation of CHB patients who received interferon therapy19 and in patients with occult HBV infection20. Our results provide new information in long-term virally suppressed patients supporting the implementation of ddPCR technology for the evaluation of cccDNA with newer and more potent antivirals undergoing clinical trial evaluation. Our results are

Table 3. Intrahepatic HBV cccDNA quantification by droplet digital (dd)PCR. a Data are expressed as median (1st quartile – 3rd quartile). b ddPCR was run on 15/17 cccDNA-positive and 34/39 cccDNA-negative liver samples after qPCR analysis. c Mann Whitney U test was used for comparison between groups.
also consistent with previous mathematical modelling of cccDNA kinetics that showed low rates of clearance in NUC-treated patients\(^\text{13}\) and provide insight into the mechanism of viral rebound after treatment withdrawal even in long-term virally suppressed patients\(^\text{15,22}\).

Similar to Lai et al., we found very low levels of intrahepatic 3.5 kb RNA and 3.5 Kb RNA/cccDNA in this cohort of long-term telbivudine-treated patients with respect to previously published cohorts of untreated patients\(^\text{14,23–25}\). Therefore, we were interested in investigating the epigenetic status of the residual intrahepatic cccDNA.

An adaptation of the cccDNA-ChIP technique\(^\text{5}\) to small biopsy samples (micro-ChIP)\(^\text{26}\) allowed the identification of an enrichment of histone PTMs associated with inactive transcription on cccDNA derived from telbivudine-treated patients. Our observation of decreased histone H3 acetylation is in accordance with previous data obtained in vivo in the context of reduced cccDNA transcriotional activity in untreated patients\(^\text{5,8,9}\). Ren et al.\(^\text{9}\) also found an increased enrichment for H3K9me3 in inactive carrier CHB patients having low 3.5 kb RNA levels, while Flecken et al.\(^\text{10}\) failed to find such a difference for trimethylation on both H3 lysine 9 and 27 across patients belonging to different CHB phases. In the same study from Flecken et al., three NUC-treated patients were also analysed, but could not be differentiated from non-treated ones on the basis of cccDNA-associated histone PTMs enrichment profile \(^\text{10}\). Our data showed that in this telbivudine-treated patient population with low 3.5 kb RNA/cccDNA ratio, H3K9me3 and H3K27me3 are enriched on histones associated with cccDNA.

Whether these changes in cccDNA-associated histone PTMs profile could be due to a direct effect of telbivudine-treatment remains to be investigated. The primary mode of action of NUCs, i.e. inhibition of HBV polymerase reverse transcriptase activity, would exclude any direct effect on cccDNA epigenome. However, one might hypothesize that a prolonged suppression of pgRNA to rcDNA conversion might trigger a negative feedback regulation of cccDNA transcription. On the other hand, we cannot rule out the hypothesis that the inhibition of cccDNA activity could be due to an additional property of telbivudine. Indeed, telbivudine was shown to modify host histone PTMs at specific loci in HepG2.2.15 cells, by restoring H3K4me3 and H3K27me3 to levels comparable to those detected in HepG2 cells\(^\text{27}\). Moreover, it has been shown that HBx protein levels may be reduced after telbivudine treatment in vitro\(^\text{28}\). Since HBx is essential for full cccDNA transcription and HBx-deficient HBV mutant strains show enrichment in cccDNA-associated histone PTMs correlated with inactive transcription\(^\text{29}\), this could represent an additional antiviral mechanism of telbivudine. If this effect on cccDNA epigenome is shared with other NUCs, or with emerging new antivirals, remains to be investigated. In this respect, recent data obtained by Balagopal et al. using single-cell laser capture microdissection and ddPCR in liver biopsies from HIV/HBV co-infected patients under antiviral therapy (DAART or ART) confirmed the decline of cccDNA amount along with the duration of the antiviral treatment and also observed a sharp decrease in preC/pgRNA levels in samples derived from long-term-treated patients\(^\text{26}\). They also showed an increased number of cccDNA-positive hepatocytes without a detectable preC/pgRNA, suggesting an inactivation of cccDNA transcriptional activity correlating with long-term antiviral therapy\(^\text{30}\). Overall, their results could be consistent with our observation of an epigenetic repression of cccDNA during long-term NUC therapy. Further single-molecule studies would be required to better clarify the relative contribution to the 3.5 Kb RNA level decrease of cccDNA template decline vs epigenetic repression.

Of course, it cannot be excluded that other liver microenvironment factors such as changes in the inflammatory status and in cytokine expression during therapy may also be involved in this phenomenon.

Altogether, using a highly sensitive cccDNA quantification method together with the analysis of the cccDNA-associated epigenome, our data showed the persistence of low levels and epigenetically-modified intrahepatic

---

**Figure 5.** Covalently closed circular DNA (cccDNA) epigenetic analysis under long-term Telbivudine treatment. Chromatin Immunoprecipitation analysis was performed using specific antibodies against H3K9me3, H3K27me3, H3K27Ac and H3K56Ac. Signal enrichment is expressed as the percentage of input cccDNA in untreated chronic hepatitis B comparative group (n = 7) (a) and Telbivudine-treated patients (n = 10) (b). Mann-Whitney U test was used to compare enrichment of specific antibodies vs the negative control (NoAb), alpha threshold = 0.05; * p < 0.05. cccDNA covalently closed circular DNA, NoAb negative control.
cccDNA in patients with long-term telbivudine-induced viral suppression. Whilst the use of liver biopsies does not prevent a sampling bias due to potential focal differences in the infected tissue, our results underline the importance of implementing more sensitive techniques to quantify cccDNA in patients and to assess the epigenetic status and transcriptional activity of the viral minichromosome. This panel of cccDNA evaluation techniques should provide an added value for the new proof of concept clinical trials aiming at a functional cure of chronic hepatitis B.

Patients and methods

Patients. Fifty-six patients with chronic hepatitis B (CHB) (46 males and 10 females) previously enrolled in the clinical studies NV-02B-007 (NCT00057265) or NV-02B-015 (NCT00131742) and who entered the CLDT600ACN04E1 (NCT00877149) study (Novartis Pharma AG) without discontinuation of telbivudine treatment were included in this study (Supplementary Fig. 1)31–33. The studies were approved by each local independent ethics committee and were in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000 and 2008. Written informed consent was obtained from each patient and/or their legal guardians.

Histological, clinical and virological data reported in this study were collected in studies NV-02B-007 or NV-02B-015 at baseline and after five years of antiviral treatment (Supplementary Fig. 1). Part of the liver specimens collected at CLDT600ACN04E1 study entry was snap frozen at − 80 °C for molecular biology analysis. These legacy clinical studies have been published with ethics committee approvals previously disclosed and publicly available31–34.

For the analysis of cccDNA histone post-translational modifications, 7 untreated CHB patients from a historical cohort collected at Hospices Civils de Lyon (Lyon’s University, France) were used as comparative samples. These patients underwent liver biopsy as part of their clinical follow-up, a fragment was preserved for research purposes and stored at − 80 °C. The protocol was approved by the competent Institutional Ethics Committee (CPP Sud est IV 11/040, authorization number DC-2008-235). Written informed consent was obtained from all patients and/or their legal guardians to undergo liver biopsy. No patients were co-infected with HIV, hepatitis C virus or hepatitis delta virus.

This submitted article is based on data from the previously submitted studies and does not involve any new studies or new human subjects. All methods were carried out in accordance with relevant guidelines/regulations. No animal experimentation and no use of primary human cells was employed in this study.

Viral load and serological assessment. Serum HBV DNA, alanine aminotransferase (ALT) levels, HBe antigen (HBeAg), HBs antigen (HBsAg) and HBe and HBs serology were analyzed in the frame of the clinical trials by the study sponsor. Serum HBV DNA levels were quantified with the Roche COBAS Amplicor PCR assay (Roche Molecular Systems, Branchburg, NJ, USA), with an estimated lower limit of detection and quantification of 300 HBV genome copies/mL (around 60 IU/mL). Other HBV serologic markers (HBsAg/anti-HBs, HBeAg/anti-HBe) were assessed using standard commercially available assays31,32.

Intrahepatic total HBV DNA, cccDNA and preC/pgRNA quantification using qPCR method. DNA was extracted from snap-frozen liver biopsies using the Master Pure DNA Purification Kit (Lucigen, Middleton, WI, USA) according to the manufacturer’s instructions. High Pure RNA Paraffin Kit (Roche Life Science, Indianapolis, IN, USA) was used for RNA extraction. Quantity and integrity of the extracted DNA and RNA were assessed by Nanodrop Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Patients’ samples were run in duplicate and in two independent experiments. Quantitative PCR were performed using specific primers and fluorescence hybridization probes previously described17 and a Light Cycler 480 Real Time PCR System (Roche Diagnostics, Manheim, Germany)24,25. Before cccDNA quantification, total DNA was treated with Plasmid-safe DNase (LUCIGEN, Middleton, WI, USA), to limit relaxed circular DNA (rcDNA) contamination. Serial dilutions of an HBV monomer plasmid (pHBV-EcoRI) were used as standard for quantification. Beta-globin quantification was performed in parallel to assess the amount of HBV DNA copies/cell 17.

Intrahepatic 3.5kb RNA (preC/pgRNA) quantification, consisting of both preCore and pgRNA transcripts, was performed with specific primers and TaqMan fluorescence hybridization probes previously described by Volz et al.23. Results were normalized over the housekeeping gene GUSb (Hs00939627_m1, ThermoFischer Scientific, Waltham, MA, USA). All the primers and probes used are listed in Supplementary Table 5 and visualized on HBV genome in Supplementary Fig. 5.

cccDNA detection using rolling circle amplification. Rolling Circle Amplification (RCA) was shown to be highly specific for complete circular forms of HBV genome and particularly adapted for the amplification of cccDNA in liver tissue with low levels of viral replication35. We assessed the presence of intrahepatic cccDNA in qPCR-negative samples using this one-step PCR method without additional steps of completion and ligation, as previously described using primers RCA1-8 listed in Supplementary Table 5 and Supplementary Fig. 6 (Fig. 2a)35,36. The amplification of circular HBV DNA was performed using Phi29 polymerase (New England Biolabs, Ipswich, MA, USA) for 21 h at 30 °C on total DNA extracted from frozen liver samples. RCA products were analysed according to two different methods to assess the presence of intrahepatic cccDNA in the samples. The first one, Southern blot after digestion of RCA products allowed us to control for RCA specificity but was not sufficiently sensitive for samples with small amount of intrahepatic cccDNA. The second one, full length-HBV genomic PCR on RCA products allowed us to detect the presence of cccDNA even at very low levels (Fig. 2)35. For Southern blot processing, RCA products were digested for 4 h at 37 °C with the restriction enzyme Spel (NEW ENGLAND BIOLABS, Ipswich, MA, USA): final volume 10 µL, RCA products 4 µL, Spel 3U and Cut-
smart gel and then transferred to perform hybridization with HBV-specific cold probes (Fig. 2b) 37.

Full-length HBV genomic PCR amplification used primers P1 and P2 36 (Supplementary Table 5 and Supplementary Fig. 6) to enhance cccDNA detection sensitivity in samples with low HBV DNA levels (Fig. 2c). The final PCR reaction included 2 μL of RCA products, 0.25 μL of each sense and anti-sense primers previously described (100 μM) and 25 μL of PrimeSTAR HS (Premix) (Takara Bio Inc. Shiga, Japan) in a 50 μL final volume. The amplification protocol was adapted from Günther et al. 38 and was performed for 40 cycles as follows: denaturation at 94 °C for 40 s; 1 min annealing at 55 °C for 10 cycles, then at 60 °C for 10 cycles and finally at 62 °C for the last 20 cycles; elongation at 68 °C for 3 min with an increment of 2 min after each 10 cycles. PCR products were run on 1% agarose gel.

Intrahepatic total HBV DNA and cccDNA quantification by droplet digital PCR. Intrahepatic total HBV DNA and cccDNA were quantified by the QX100 Droplet Digital PCR System (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s instructions. Before cccDNA quantification, total DNA was treated with Plasmid-safe DNAse (Lucigen, Middleton, WI, USA), to limit rcDNA contamination. Briefly, the 25 μL ddPCR reaction was comprised of 2× ddPCR Supermix for probes (Bio-Rad, Hercules, CA, USA), 900 nM HBV cccDNA forward and reverse primers, 250 nM HBV probe, and 5 μL of DNA sample. The plates were loaded with required consumables into the Automated Droplet Generator to partition the sample around 20,000 droplets in 20 μL. PCR amplification was performed in a C1000 Touch thermal cycler (Bio-Rad, Hercules, CA, USA) with the following amplification program: 10 min at 95 °C, 40 cycles of denaturation for 30 s at 94 °C and annealing for 60 s at 60 °C (ramping rate set to 2 °C/s), final incubation step for 10 min at 98 °C. After reading in a QX100 Droplet Reader (Bio-Rad, Hercules, CA, USA), the data were analyzed using the QuantaSoft analysis software (Bio-Rad, Hercules, CA, USA), which automatically calculated absolute sample concentration after applying Poisson’s distribution. Fluorescence amplitude threshold to distinguish positive from negative droplets was based on amplification of negative controls (water and non-HBV infected samples, Fig. 3). Comcomitant quantification of HBV DNA and beta-globin in the same sample allowed the estimation of HBV DNA or cccDNA copies/cell. All primers and probes used are listed in Supplementary Table 5 and Supplementary Fig. 5. The pBR322-HBV construct was used to assess linearity of ddPCR quantification and to compare it to qPCR. Limit of detection for cccDNA quantification in ddPCR was 4.8 copies/10^6 cell (3.3–7, 95% confidence interval), calculated by Probit analysis on a sample composed of serial dilution of a minicircle HBV into genomic DNA.

Specificity of cccDNA assay for episomal HBV DNA vs integrated sequences was analyzed in Hep3B cells, which harbor nearly 1 HBV integration/cell, but no cccDNA (Supplementary Methods and Supplementary Fig. 3a,b). cccDNA assay was specific for cccHBV DNA vs rcDNA if the rcDNA:cccDNA ratio was <1000 without the need of prior PSD digestion (Supplementary Fig. 3c). In HBV-infected HepG2-NTCP cells, NUC treatment by lamivudine (3TC) lowers the rcDNA:cccDNA to less than 100 and addition of PSD digestion ensures a rcDNA:cccDNA around 1, thus highly incrementing the specificity of our assay for cccDNA (Supplementary Methods and Supplementary Fig. 3d). Thus, these data supported the use of this ddPCR cccDNA protocol for specific cccDNA quantification over other HBV genomic forms in the long-term NUC-treated patients analyzed in this study.

Chromatin immunoprecipitation from frozen liver biopsies. ChIPs from liver biopsies were performed as described by Testoni et al. 36. Briefly, frozen biopsies were removed from the freezer and immediately added with PBS/1% formaldehyde and incubated 10 min at room temperature. Crosslinking reaction was quenched with 0.125 M glycine. After centrifugation, the cross-linked biopsy was resuspended in lysis buffer (50 mM Tris–HCl pH 8, 10 mM EDTA, 1% SDS, protease inhibitors) and homogenized with the help of a pestle. Supernatant was then sonicated in a Bioruptor (DIAGENODE, Liege, Belgium) for 2×30 s cycles, diluted 1:10 in RIPA Buffer (10 mM Tris–HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 1% Na-deoxycholate, protease inhibitors) and incubated with Dynabeads Protein G and 3 μg of each antibody (ChIP-grade anti-H3K27Ac, H3K56Ac, H3K9me3, H3K27me3, DIAGENODE, Liege, Belgium) overnight at 4 °C rotating. After immunoprecipitation, washes and reverse crosslinking, the samples were extracted twice with phenol/chloroform, once with chloroform and ethanol precipitated in the presence of 30 μg of glycogen (SIGMA ALDRICH-MERCK, Darmstadt, Germany). Quantitative PCR was performed using cccDNA-specific primers and probes. Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) promoter region amplification served as control for specific enrichment of antibodies (see Supplementary Table 5 and Supplementary Fig. 4a).

Statistical analyses. Statistical analysis was performed using Prism 7 software (GRAPHPAD SOFTWARE, San Diego, CA, USA). Mann Whitney U Test and Kruskal Wallis test were used to compare numerical data and Chi-square test was used to compare frequencies between groups, with Fisher’s exact test correction if appropriate. Probit analysis was performed using SPSS 18.0 (SPSS Inc, Chicago, IL).

Received: 2 April 2020; Accepted: 17 November 2020
Published online: 03 December 2020

References
1. de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180–e190 (2020).
6. Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104–1108 (1996).

7. Hong, X., Kim, E. S. & Guo, H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatol. Baltim. Md 66, 2066–2077 (2017).

8. Pollincino, T. et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H1 histones. Gastroenterology 130, 823–837 (2006).

9. Ren, J.-H. et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3–9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatol. Baltim. Md 68, 1260–1276 (2018).

10. Flecken, T. et al. Mapping the heterogeneity of histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients. J. Virol. 93 (2019).

11. Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfec tion efficiently deplete nuclear cccDNA in vivo. Gut 67, 542–552 (2018).

12. Zeisel, M. B. et al. Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut https://doi.org/10.1136/gutjnl-2014-308943 (2015).

13. Boyd, A. et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J. Hepatol. 65, 683–691 (2016).

14. Lai, C.-L. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).

15. Mu, D., Yan, L., Tang, H. & Liao, Y. A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system. Biotechnol. Lett. 37, 2063–2073 (2015).

16. Mu, D. et al. Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy. Sci. Rep. 7, 5937 (2017).

17. Caviglia, G. P. et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J. Hepatol. https://doi.org/10.1016/j.jhep.2017.03.021 (2017).

18. Tropper, P. et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc. Natl. Acad. Sci. U. S. A. 112, E5715–5724 (2015).

19. Testoni, B., Durantel, D. & Zoulim, F. Novel targets for hepatitis B virus therapy. Liver Int. 37, 33–39 (2017).

20. Völz, T. et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBsAg-negative patients. Gastroenterology 133, 843–852 (2007).

21. Lebossé, F. et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J. Hepatol. 66, 897–909 (2017).

22. Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615–625 (2019).

23. Testoni, B. et al. Ribavirin restores IFNa responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 65, 672–682 (2016).

24. Tian, Y. et al. Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B. Carcinogenesis 35, 53–61 (2014).

25. Zhang, S. et al. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 392, 94–104 (2017).

26. Belloni, L. et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl. Acad. Sci. U. S. A. 106, 19975–19979 (2009).

27. Balagopal, A. et al. Single hepatocyte hepatitis B virus transcriptional landscape in HIV co-infection. J. Infect. Dis. https://doi.org/10.1093/infdis/jiz067 (2019).

28. Hou, J. et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatol. Baltim. Md 47, 447–454 (2008).

29. Hou, J.-L. et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. Adv. Ther. 32, 727–741 (2015).

30. Lai, C.-L. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576–2588 (2007).

31. Zeuzem, S. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 51, 11–20 (2009).

32. Margeridon, S. et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob. Agents Chemother. 52, 3068–3073 (2008).

33. Martel, N., Gomes, S. A., Chemin, I., Trépo, C. & Kay, A. Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA). J. Virol. Methods 193, 653–659 (2013).

34. Lucifora, J. et al. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Res. 145, 14–19 (2017).

35. Günther, S. et al. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69, 5437–5444 (1995).

Acknowledgements

We thank Delphine Bousquet and Dr. Sofía Perez del Pulgar for helping with the Probit analysis and Janine French for reading the manuscript.
Author contributions
FL, A.I., M.L., C.M., A.D., J.F. performed experiments; F.C. performed experiments in Hep3B and HBV-infected HepG2-NTCP cells; F.L., B.T. analyzed results, interpreted the data and drafted the manuscript; K.H. retrieved clinical data and revised the manuscript; F.Z. supervised experiments, interpreted the data and substantively revised the manuscript.

Funding
This work was supported by research grants from Novartis Pharma AG and from «Agence Nationale pour la Recherche sur le SIDA et les hepatitis virales» (ANRS) to FZ; ML was supported by an ANRS fellowship and AI was supported by a Convention Industrielle de Formation par la REcherche (CIFRE) fellowship funded by the French Ministry of Higher Education based on the convention between INSERM and Sanofi.

Competing interests
FL, AI, ML, CM, AD, JF, FC declare no conflicts of interest. KH was a formerly Novartis employee. FZ and BT received grants from Evotec, Hoffmann-La Roche and Novartis.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-78001-1.

Correspondence and requests for materials should be addressed to B.T. or F.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020